ERAS
Erasca, Inc. · Healthcare
16.49
3.67%(-0.63)
Market OpenLast Updated: — ET
52W L: $1.0152W H: $18.20
$16.48
CHG+0.87 (+5.55%)
H$18.45
L$12.90
VOL89M
ERAS (1h)
Erasca, Inc. · Healthcare
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $18.20 and last traded at $17.12, with a volume of 5250452 shares traded. The stock had previously closed at $17.81. Wall Street Analyst Weigh In Several analysts have recently issued
JPMorgan Chase and Co. trimmed its stake in shares of Erasca, Inc. (NASDAQ: ERAS) by 7.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,269,042 shares of the company's stock after selling 103,527 shares during the period.
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) insider Ebun Garner sold 80,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $16.40, for a total value of $1,312,000.00. Following the completion of the sale, the insider owned 25,076 shares of the company's stock, valued
20,000 shares of Common Stock were exercised from options and sold on March 4, 2026, yielding a transaction value of ~$301,000 at a weighted average price of $15.04 per share. The activity represented 100.00% of Shannon's direct Common Stock holdings, reducing direct post-transaction ownership of this share class to zero.
Erasca, Inc. (NASDAQ: ERAS - Get Free Report)'s share price rose 10.3% on Thursday following a stronger than expected earnings report. The company traded as high as $14.94 and last traded at $14.89. Approximately 4,689,563 shares were traded during trading, a decline of 27% from the average daily volume of 6,459,411 shares. The stock had previously
Shares of Erasca, Inc. (NASDAQ: ERAS - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating on the
Garner Ebun
officer: Chief Legal Officer
80,000 SH @ $1.70
2026-04-01
Garner Ebun
officer: Chief Legal Officer
80,000 SH @ $1.70
2026-04-01
Garner Ebun
officer: Chief Legal Officer
80,000 SH @ $16.40
2026-04-01
Morris Shannon
officer: Chief Medical Officer
20,000 SH @ $1.70
2025-03-04
Morris Shannon
officer: Chief Medical Officer
20,000 SH @ $1.70
2026-03-04
Morris Shannon
officer: Chief Medical Officer
20,000 SH @ $15.04
2026-03-04
Lim Jonathan E
director, 10 percent owner, officer: Chairman & CEO
2,000,000 SH @ $10.31
2026-01-29
Chacko David M.
officer: CFO and CBO
640,000 SH @ $10.31
2026-01-29